Google
Apple
English (UK)
English (India)
English (Canada)
Deutsch (Deutschland)
Deutsch (Österreich)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
ROCHE HOLDING AG |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 224.9 CHF | 0.00% |
|
-3.93% | -8.02% |
| Feb. 09 | Swiss Market Index Closes Lower Ahead of Key Inflation Data | MT |
| Feb. 09 | Roche Confirms Planned Job Cuts in Pharma Product Development Segment | MT |
| Sales 2024 * | 60.39B 69B | Sales 2025 * | 64.28B 73.45B | Capitalization | 181B 207B |
|---|---|---|---|---|---|
| Net income 2024 * | 13.53B 15.46B | Net income 2025 * | 15.29B 17.47B | EV / Sales 2024 * | 3.17 x |
| Net Debt 2024 * | 10.76B 12.29B | Net Debt 2025 * | 3.82B 4.36B | EV / Sales 2025 * | 2.87 x |
| P/E ratio 2024 * |
13.1
x | P/E ratio 2025 * |
11.7
x | Employees | 103,605 |
| Yield 2024 * |
4.34% | Yield 2025 * |
4.49% | Free-Float | 88.06% |
More Fundamentals
* Assessed data
More news
Latest transcript on Roche Holding AG
More press releases
| 1 week | -3.93% | ||
| Current month | -8.98% | ||
| 1 month | -11.42% | ||
| 3 months | -5.01% | ||
| 6 months | -15.74% | ||
| Current year | -8.02% |
1 week
222.75
234.00
1 month
222.75254.20
Current year
222.75255.90
1 year
222.75293.55
3 years
222.75404.20
5 years
222.75404.20
10 years
206.35404.20
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 49 | 02-12-31 | |
Severin Schwan
CHM | Chairman | 57 | 07-12-31 |
Alan Hippe
DFI | Director of Finance/CFO | 57 | 11-03-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Bernard Poussot
BRD | Director/Board Member | 72 | 15-03-02 |
| Director/Board Member | 59 | - | |
| Director/Board Member | 65 | 95-12-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 9.03% | 121 M€ | -.--% | ||
| 8.46% | 19 M€ | +2.97% | - | |
| 4.67% | 2 M€ | -.--% | ||
| 2.85% | 6 M€ | -.--% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-02-09 | 224.9 | 0.00% | 1,326,187 |
| 24-02-08 | 224.9 | -1.45% | 1,387,393 |
| 24-02-07 | 228.2 | -1.02% | 2,318,773 |
| 24-02-06 | 230.6 | +0.02% | 1,930,911 |
| 24-02-05 | 230.5 | -1.54% | 1,735,083 |
Delayed Quote Swiss Exchange, February 09, 2024 at 11:30 am EST
More quotes
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
Pharmaceuticals
Calendar
2024-02-22
- Citi Virtual Oncology Leadership Summit
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A+
Sell
Buy
Mean consensus
HOLD
Number of Analysts
19
Last Close Price
224.9
CHF
Average target price
290.2
CHF
Spread / Average Target
+29.05%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -8.02% | 207 B $ | |
| +26.97% | 666 B $ | |
| +19.17% | 536 B $ | |
| +0.01% | 377 B $ | |
| +15.07% | 318 B $ | |
| +12.33% | 307 B $ | |
| +4.05% | 206 B $ | |
| -7.92% | 191 B $ | |
| -4.27% | 156 B $ | |
| -3.63% | 117 B $ |
